RxDoctor Payments Data

Ramesh Arora, MD

Interventional Cardiology · van Nuys, CANPI 1619964095

Payments from drug & device makers

$18,161in general payments, 2019–2025

Across 109 payments — averaging $166.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor (international) Ltd.$15K
  • Abbott$2K
  • Novartis$317
  • Gilead$177
  • Amgen$151
  • AstraZeneca$122
  • plus $480 from 7 others

What the payments were for

  • Food & beverage$3,097100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,161 in reported general payments places this provider in the 60th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$1,434,207
Medicare patients
578
Services billed
9,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban176$170,810
EntrestoSacubitril/Valsartan62$73,721
VascepaIcosapent Ethyl47$17,564
BrilintaTicagrelor32$14,089
Ranolazine ErRanolazine171$12,907
Nitroglycerin725$11,925
Metoprolol Succinate716$5,679
Isosorbide Mononitrate ErIsosorbide Mononitrate527$3,965
Fenofibrate19$3,154
Icosapent Ethyl21$2,546
Propranolol Hcl171$2,382
Rosuvastatin Calcium316$2,268
Cilostazol184$2,200
Hydralazine Hcl268$2,167
Atorvastatin Calcium453$2,110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$170,810176 claims
NovartisEntresto$317$73,72162 claims
AstraZenecaBrilinta$122$14,08932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in van Nuys

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →